The technology disclosed in the present application generally relates to handle assemblies for intravascular treatment devices and associated systems and methods. In particular, several embodiments are directed to handle assemblies for intravascular treatment devices for achieving intravascular, thermally-induced renal neuromodulation.
Hypertension, heart failure and chronic kidney disease represent a significant and growing global health issue. Current therapies for these conditions include non-pharmacological, pharmacological and device-based approaches. Despite this variety of treatment options, the rates of control of blood pressure and the therapeutic efforts to prevent progression of heart failure and chronic kidney disease and their sequelae remain unsatisfactory. Although the reasons for this situation are manifold and include issues of non-compliance with prescribed therapy, heterogeneity in responses both in terms of efficacy and adverse event profile, and others, it is evident that alternative options are required to supplement the current therapeutic treatment regimes for these conditions.
Reduction of sympathetic renal nerve activity (e.g., via denervation) can reverse these processes. Ardian, Inc., of Palo Alto, Calif., has discovered that an energy field, including and comprising an electric field, can initiate renal neuromodulation via denervation caused by irreversible electroporation, electrofusion, apoptosis, necrosis, ablation, thermal alteration, alteration of gene expression or another suitable modality.
The present disclosure describes handle assemblies for intravascular treatment devices and associated systems and methods.
Although the following description provides many specific details of the following examples in a manner sufficient to enable a person skilled in the relevant art to practice, make, and use them, several of the details and advantages described below may not be necessary to practice certain examples and methods of the disclosure. Additionally, the disclosure may include other examples and methods that are within the scope of the claims but are not described in detail.
Reference throughout this specification to “one example,” “an example,” “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present disclosure. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, steps or characteristics may be combined in any suitable manner in one or more examples of the disclosure. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed disclosure.
The system 10 includes an intravascular treatment device 12. The treatment device 12 includes an elongated shaft 16 having a proximal end region 18 and a distal end region 20. The treatment device 12 provides access, e.g., to the renal plexus (RP), through an intravascular path that leads to a respective renal artery, as
Different sections of the elongated shaft 16 serve different mechanical functions when in use. The sections are thereby desirably differentiated in terms of their size, configuration, and mechanical properties for (i) percutaneous introduction into a femoral artery through a small-diameter access site; (ii) atraumatic passage through the tortuous intravascular path through an iliac artery, into the aorta, and into a respective left/right renal artery, including (iii) significant flexure near the junction of the left/right renal arteries and aorta to gain entry into the respective left or right renal artery; (iv) controlled translation, deflection, and/or rotation within the respective renal artery to attain proximity to, and a desired alignment with, an interior wall of the respective renal artery; and (v) the placement of at least one thermal element 24 (e.g., a thermal heating element) carried by the distal end region 20 into contact with tissue on the interior wall. The thermal element 24 is specially sized and configured for manipulation and use within a renal artery.
The proximal end region 18 of the elongated shaft 16 includes a handle assembly 200. The handle assembly 200 is sized and configured to be securely or ergonomically held and manipulated by a caregiver (see, e.g.,
The distal end region 20 of the elongated shaft 16 can flex in a substantial fashion to gain entrance into a respective left/right renal artery by manipulation of the elongated shaft 16, e.g., via passage within a guide catheter (not shown). Once entrance to a renal artery is gained, further manipulation of the distal end region 20 and the thermal heating element 24 within the respective renal artery establishes proximity to and alignment between the thermal heating element 24 and tissue along an interior wall of the respective renal artery. In some embodiments, manipulation of the distal end region 20 will also facilitate contact between the thermal heating element 24 and wall of the renal artery.
The system 10 also includes a thermal generator 26 (e.g., a thermal energy generator). Under control of the caregiver or automated control algorithm 102, the generator 26 generates a selected form and magnitude of thermal energy. A cable 28 operatively attached to the handle assembly 200 electrically connects the thermal heating element 24 to the generator 26. At least one supply wire 29 (see, e.g.,
For systems that provide for the delivery of a monopolar electric field via the thermal heating element 24, a neutral or dispersive electrode 38 can be electrically connected to the generator 26. Additionally, one or more sensors 52 (see
As seen in
The complex, multi-bend structure formed by the proximal, intermediate and distal flexure zones 32, 34, and 44 of the distal end region 20 of the elongated shaft 16 create a consistent and reliable active surface area of contact between the thermal heating element 24 and tissue within the respective renal artery. Once proximity between, alignment with, and contact between the thermal heating element 24 and tissue are established within the respective renal artery, the purposeful application of energy from the generator 26 to tissue by the thermal heating element 24 induces one or more desired thermal heating effects on localized regions of the renal artery and adjacent regions of the renal plexus (RP), which lay intimately within or adjacent to the adventitia of the renal artery. The purposeful application of the thermal heating effects can achieve neuromodulation along all or a portion of the RP.
The thermal heating effects can include both thermal ablation and non-ablative thermal alteration or damage (e.g., via sustained heating and/or resistive heating). Desired thermal heating effects may include raising the temperature of target neural fibers above a desired threshold to achieve non-ablative thermal alteration, or above a higher temperature to achieve ablative thermal alteration. For example, the target temperature can be above body temperature (e.g., approximately 37° C.) but less than about 45° C. for non-ablative thermal alteration, or the target temperature can be about 45° C. or higher for the ablative thermal alteration.
With reference to
Rotation of the elongated shaft 16 when the intermediate flexure zone 34 is deflected within the respective renal artery causes the thermal heating element 24 to rotate within the respective renal artery, making it easier to achieve contact with the vessel wall, to determine whether there is wall contact (particularly in planes where there is poor angiographic visualization), and/or to angularly reposition the thermal heating element. Rotation may be combined with translation of the thermal heating element 24 for repositioning of the thermal heating element at a different angular and longitudinal position within the respective renal artery for delivery of energy at multiple locations within the renal artery. Since there are cables and wires running from the handle assembly through the shaft of the device (e.g., actuation wire/cable, electrical transmission wire(s), thermocouple wire(s), etc.), it is desirable to limit rotation of the shaft relative to these wires in order to avoid unnecessary entanglement and twisting of these wires; handle assembly 200 therefore comprises a rotational limiting element, as described in more detail below.
As seen in the exploded view of
As described in more detail below, in the assembled configuration the actuator 260 and carrier 280 are constrained within the housing assembly 240 in a manner that facilitates coordinated angular rotation of the actuator and linear translation of the carrier. As also described in more detail below, proximal linear translation of carrier 280 relative to the housing assembly 240, via caregiver proximal rotation of actuator 260, causes deflection of thermal heating element 24 about intermediate flexure zone 34 of the distal end region 20 of the elongate shaft 16. Optional O-ring 275, positioned between the actuator 260 and the lower housing 244, may provide tactile feedback or resistance to the caregiver during such caregiver rotation of the actuator, and/or may maintain the actuator in proximally rotated position. An alternative actuation mechanism can include a sliding actuator directly or indirectly connected to a control wire, wherein caregiver sliding of the sliding actuator causes linear translation of the control wire relative to the housing assembly and deflection of the thermal heating element about the intermediate flexure zone. Yet another alternative actuation mechanism can include a rotational actuator directly or indirectly connected to a control wire, wherein caregiver rotating of the rotating actuator causes linear translation of the control wire relative to the housing assembly and deflection of the thermal heating element about the intermediate flexure zone.
After assembly of the housing 240, the inner limiter ring 210 is positioned concentrically over a distal portion of the housing assembly 240, the outer limiter ring 220 is positioned concentrically over the inner limiter ring 210, and the rotator is positioned concentrically over the outer limiter ring 220. Proximal strain relief 202 is affixed to a proximal portion of the housing assembly 240, while distal strain relief 204 is affixed to a distal portion of the rotator 230. As described in more detail below, the inner limiter ring 210, the outer limiter ring 220 and the rotator 230 act in concert with the housing assembly 240 to facilitate rotation of elongated shaft 16 without rotation of the handle assembly 200, as well as to limit rotation of the elongated shaft.
Treatment device 12 comprises control wire 40 that extends the length of elongated shaft 16 (e.g., along the length or within a lumen of the elongated shaft) from the handle assembly 200 of proximal end region 18 to the intermediate flexure zone 34 of the distal end region 20. The control wire terminates distally in the distal end region 20 and, as seen in
Optionally, the control wire 40 may be elastic and/or may be connected to an elastic element, such as a spring, to dampen the force applied to the control wire by translation of the carrier 280, thereby dampening the buckling or bending moment applied to the intermediate flexure zone 34. This may provide a more consistent contact force between the thermal heating element 24 and the vessel wall. It also may facilitate maintenance of stable contact as the vessel wall moves relative to the elongated shaft.
By rotating the actuator 260 proximally, the caregiver may proximally translate the carrier 280 relative to the housing assembly 240 in order to proximally retract the control wire 40 relative to the elongated shaft 16, thereby deflecting the intermediate flexure zone 34 of the distal end region 20. Actuator 260 comprises an actuator body 262 having a pivot 264, as well as a cam 266 that is positioned on the surface of the actuator that faces upper housing 242 and carrier 280 in the assembled configuration.
Actuator 260 also has as an actuator button 270 that is coupled to the actuator body via an actuator button arm 272. The actuator button arm 272 acts as a lever arm that provides additional torque and mechanical advantage during rotation of the actuator 260. The actuator button 270 optionally has a larger width than the actuator button arm 272 to facilitate tactile manipulation and ergonomic handling of the actuator button by a caregiver. The actuator button 270 initially is positioned in a forward or distal position relative to housing assembly 240. The caregiver may pull back (i.e. proximally) on the button 270 to proximally rotate the actuator 260 relative to the housing assembly and deflect the intermediate flexure zone 34 of the distal end region 20. The range of distances separating the actuator button 270 from the rotator 230 during caregiver manipulation of the handle assembly 200 is specified in a manner that facilitates single-handed ergonomic use of the handle assembly 200, even when the actuator button 270 is positioned in its proximal-most or distal-most position relative to the housing assembly 240.
The housing assembly 240 (illustratively, the lower housing 244) comprises an actuator post 248 that is placed within the actuator's pivot 264. The actuator post 248 constrains translation of the actuator 260 relative to the housing assembly 240, while facilitating angular rotation of the actuator about the actuator post 248 and the actuator's pivot 264, which is the actuator's axis of rotation. The actuator post 248 facilitates proper alignment of the actuator 260 relative to the housing assembly 240 and the carrier 280, and may reduce a risk of actuator binding during angular rotation of the actuator. The actuator post 248 also may comprise a mating feature 246 of the housing assembly 240.
Upon mating of the upper housing 242 and the lower housing 244 to form the housing assembly 240, actuator button arm 272 of the actuator 260 is seated within the actuator channel 250 formed through the mating of the upper and lower housings (see
The carrier 280 comprises first and second housing posts 282a and 282b that are positioned within first and second longitudinal channels 252a and 252b, respectively, of the lower housing 244 of housing assembly 240. The carrier 280 also comprises fin 281 that is positioned within channel 251 of the lower housing 244. The carrier comprises a cam post 286 that is seated within the actuator's cam 266. Furthermore, the carrier comprises one or more attachment points or features 288 whereat the control wire 40 is proximally coupled to the carrier 280. As seen in
Positioning of the carrier's first and second housing posts 282a and 282b within the lower housing's first and second longitudinal channels 252a and 252b, as well the carrier's fin 281 within the lower housing's channel 251, constrains rotation of the carrier 280 relative to the housing assembly 240, while facilitating translation of the carrier relative to a longitudinal axis of the housing assembly. Optionally, interaction of the carrier's first and second housing posts with the housing assembly's first and second longitudinal channels may limit a degree of such longitudinal translation of the carrier relative to the housing assembly as the carrier's housing posts abut the proximal and/or distal ends of the lower housing's longitudinal channels. This, in turn, may limit deflection of the intermediate flexure zone 34 of the distal end region 20 of the elongated shaft 16 via the proximal connection of control wire 40 to the carrier 280 and the distal connection of the control wire to the intermediate flexure zone, and/or may limit rotation of the actuator relative to the housing assembly due to the interaction (described in more detail below) between the carrier's cam post 286 and the actuator's cam 266.
As mentioned, the carrier's cam post 286 is positioned within the actuator's cam 266. When the actuator button 270 is positioned in its distal-most position relative to the housing assembly 240, as in
As the carrier's cam post 286 traverses the actuator's cam 266 from inferior to superior during the caregiver's rotation of the actuator button 270 from a more distal position (as in
Conversely, as the carrier's cam post 286 traverses the actuator's cam 266 from superior to inferior during rotation of the actuator button 270 from a proximal position to a distal position relative to the housing assembly 240, the decreased distance between the actuator's pivot 264 and cam 266 from superior to inferior causes the actuator's cam 266 to apply a force to the carrier's cam post 286 positioned therein. This force decreases the distance between the actuator's pivot 264 and the carrier's cam post 286 that is positioned within the actuator's cam 266 and translates the carrier 280 distally relative to a longitudinal axis of the housing assembly 240. Such distal translation of the carrier relative to the housing assembly allows the intermediate flexure zone 34 to straighten via removal of tension applied by the carrier to control wire 40. Alternatively, as the carrier translates distally (e.g., due to a restoring force applied to the carrier by the deflected intermediate flexure zone 34 via the control wire 40), the carrier's cam post 286 may apply a force to the actuator's cam 266 that moves the cam post 286 from superior to inferior within the actuator's cam 266 and rotates the actuator button 270 distally.
As will be apparent to those of skill in the art, the length of the housing assembly's first and/or second longitudinal channels 252a and 252b optionally may limit longitudinal translation of the carrier 280 relative to the housing assembly 240. Furthermore, the difference between the distances D2 and D1 (i.e., D2−D1) optionally may define a maximum translation distance of the carrier 280 relative to the housing assembly 240. Furtherstill, the geometry of the actuator's cam 266 optionally may be altered to alter the amount of linear translation of carrier 280 that results from a given amount of angular rotation of actuator 260, and vice versa.
The geometry of cam 266 optionally may be configured to interact with cam post 286 in a manner that provides variable resistance to the caregiver during rotation of the actuator 260. For example, resistance may increase as the actuator is rotated more proximally. At the limit, such increased resistance may serve as a brake that precludes further proximal rotation of the actuator relative to the housing assembly.
As discussed previously, the control wire 40 extends from the distal end region 20 of elongated shaft 16 to attachment features 288 of the carrier 280. Proximal longitudinal translation of the carrier 280 relative to the housing assembly 240 (i.e., proximal rotation of the actuator 260 relative to the housing assembly) places the control wire 40 in tension, which deflects the intermediate flexure zone 34. Conversely, distal longitudinal translation of the carrier 280 relative to the housing assembly 240 (i.e., distal rotation of the actuator relative to the housing assembly) reduces or eliminates tension in the control wire, which may reduce or eliminate deflection of the intermediate flexure zone 34. A geometric constraint defined by a length of the housing assembly's actuator channel 250, in combination with a distance between the axis of rotation of the actuator 260 and the actuator button arm 272 as it abuts either end of the channel 250, optionally may define a maximum arc length and degree of rotation that may be traversed by the actuator during its rotation about the housing's actuator post 248, which in turn may define a maximum deflection of the intermediate flexure zone 34 of distal end region 20. Alternatively/additionally, a geometric constraint limiting deflection of the intermediate flexure zone 34 may be defined by interaction of the actuator with the carrier 280 (e.g., the carrier's cam post 286 abutting either end of the actuator cam 266), by interaction of the carrier with the housing assembly (e.g., the carrier's first and/or second housing posts 282a and 282b abutting either end of the lower housing's first and/or second longitudinal channels 252a and 252b, respectively, and/or the lower housing's actuator post 248 or a housing mating feature 246 abutting either end of the carrier's channel 284) and/or by a maximum deflection capacity of the intermediate flexure zone 34 of distal end region 20 as conveyed to the handle assembly via control wire 40 attached to the carrier 280.
The actuator 260 optionally may comprise male O-ring attachment profile 274 on the surface of the actuator that faces lower housing 244 in the assembled configuration (see
Likewise, lower housing 244 optionally may comprise optional female O-ring attachment profile 249. The female O-ring attachment profile may have a maximum inner cross-sectional dimension that is just slightly larger than the outer diameter of the O-ring 275. The female attachment profile 249 optionally may be slightly non-circular or pointed, as well, e.g., may have a profile similar to that of the actuator's male attachment profile 274.
Upon mating of the upper housing 242 and the lower housing 244 to form the housing assembly 240, O-ring 275 is positioned within the female O-ring attachment profile 249 of the lower housing 244 and over the male O-ring attachment profile 274 of the actuator 260. With the actuator positioned distally relative to the housing assembly, the non-circular male and female O-ring attachment profiles preferably are concentric, such that the O-ring is in an unstressed state during shipping and storage.
As the actuator button 270 is rotated from a more distal position to a more proximal position within the actuator channel 250, the actuator's male attachment profile 274 is no longer concentric with the lower housing's female attachment profile 249. This may cause engagement of the O-ring 275 between the relatively pointed sections of the actuator's male attachment profile 274 and the lower housing's female attachment profile 249. Such O-ring engagement increases friction, which may provide tactile feedback to the caregiver and/or may provide a friction lock that temporarily maintains the rotational position of the actuator 260 (and thereby the translational position of the carrier 280 and the control wire 40) relative to the housing assembly 240.
As the actuator button 270 is rotated proximally within the actuator channel 250, thereby proximally translating the carrier 280 and deflecting the intermediate flexure zone 34 of the distal end region 20 via the control wire 40, the intermediate flexure zone 34 may convey a restoring moment to the actuator 260 through the control wire and the carrier. The restoring moment may seek to reverse deflection of the intermediate flexure zone and rotate the actuator button 270 back to a more distal position within the actuator channel 250. The increased friction provided by engagement of the O-ring 275 may counteract the intermediate flexure zone's restoring moment to temporarily maintaining deflection of the intermediate flexure zone 34. Alternative friction and locking mechanisms known in the art may be provided.
As discussed previously, cable 28 of system 10 is operatively attached to the handle assembly 200 and electrically connects the thermal heating element 24 at the distal end region 20 of the elongated shaft 16 to the generator 26. The cable 28 may be either removably attached (e.g., via a plug or other cable connector) or permanently attached (e.g., via adhesives and/or solder) to the handle assembly 200. Optionally, the cable may comprise a rotational electrical coupling that facilitates independent rotation of the handle assembly 200 relative to the cable 28. As seen in
In the embodiments of
In
Supply wire(s) 29 extend distally from circuit board 290. Along with control wire 40, the supply wire(s) 29 pass through a distal lumen of the handle assembly 200 formed through housing assembly 240, rotator 230 and distal strain relief 204, then along the elongated shaft 16 or through a lumen in the elongated shaft 16 from the handle assembly 200 to the thermal heating element 24. The elongated shaft 16 is coupled proximally to rotator 230 and/or to distal strain relief 204 (and thereby to the rotator).
As will be discussed later in greater detail, it is desirable to rotate the distal end region 20 of the elongated shaft 16 of the treatment device 12 within the renal artery after the thermal heating element 24 is in contact with the vessel wall. However, it may be cumbersome and awkward for a clinical practitioner to rotate the entire handle assembly 200 at the proximal end of the device 12, particularly given the dimensions of the renal anatomy. Rotation of the rotator 230 relative to the housing assembly 240 causes the elongated shaft 16 to rotate about its longitudinal axis without rotation of the handle assembly 200 (i.e., without rotation of the housing assembly 240).
Since control wire 40 and supply wire(s) 29 proximally terminate within the housing assembly 240, significant independent rotation of the elongated shaft relative to the housing assembly might cause the wires to become significantly twisted about one another and/or to break. Optionally, one or more mechanical and/or electromechanical rotational couplings may be provided to connect the more proximal portion of the control wire 40 that is connected to the carrier to the more distal portion of the control wire that travels through the elongated shaft 16, and/or to connect the more distal portions of the supply wire(s) 29 in the elongated shaft 16 to the more proximal portion of the supply wire(s) in the housing assembly 240. Rotational couplings may facilitate independent rotation of the elongated shaft relative to the housing assembly without significant control wire and/or supply wire twisting, while maintaining electrical conductivity along the full length(s) of the supply wires.
Additionally or alternatively, a rotation limiting element may be provided to limit independent rotation of the elongated shaft 16 relative to the handle assembly 200. With reference now to
As discussed previously, the inner limiter ring 210 is positioned concentrically over a distal portion of the housing assembly 240, the outer limiter ring 220 is positioned concentrically over the inner limiter ring 210, and the rotator 230 is positioned concentrically over the outer limiter ring 220. The distal portion of the housing assembly 240 comprises cylindrical segment 254 about which the inner limiter ring 210 is concentrically positioned. The cylindrical segment is of reduced diameter relative to surface 241 of the housing assembly 240 just proximal of the cylindrical segment 254, such that proximal surfaces of the inner limiter ring 210, the outer limiter ring 220 and the rotator 230 abut surface 241 of the housing assembly 240. These abutments may constrain proximal translation of the inner limiter ring 210, the outer limiter ring 220 and/or the rotator 230 relative to the housing assembly 240.
An inner diameter of inner limiter ring 210 is just slightly greater than an outer diameter of the housing assembly's cylindrical segment 254, such that the inner limiter ring may rotate concentrically about the cylindrical segment. Likewise, an inner diameter of outer cylindrical segment 222 of outer limiter ring 220 is just slightly greater that an outer diameter of inner cylindrical segment 212 of the inner limiter ring 210, such that the outer limiter ring may rotate concentrically about the inner limiter ring. Finally, an inner diameter of a proximal region of the rotator 230 is just slightly greater than an outermost diameter of the outer limiter ring 220 at outer tab 224, such that the rotator may rotate concentrically about the outer limiter ring.
The geometric configuration of handle assembly 200 facilitates independent rotation of the rotator 230 relative to the housing assembly 240, while constraining longitudinal translation of the rotator relative to the housing assembly. Via its connection to the rotator, the elongated shaft 16 likewise may be rotated without rotating the handle assembly 200 (i.e., without rotating the housing assembly 240), while translation of the handle assembly also translates the elongated shaft. The distal portion of the housing assembly 240 comprises housing shaft 256 (located distally and of reduced cross-section relative to the housing assembly's cylindrical segment 254) having lumen 257. Rotator 230 comprises rotator shaft 232 having lumen 233 and configured for positioning within the lumen 257 of the housing shaft 256 when the rotator 230 is attached to the housing assembly 240 to facilitate independent rotation of the rotator relative to the housing assembly.
Rotator 230 optionally may comprise one or more rotator elements 234 that engage or rub against cylindrical segment 254 of housing assembly 240 to provide tactile feedback to the caregiver during rotation of the rotator relative to the housing assembly 240. All or a portion of the cylindrical segment 254 optionally may comprise a surface pattern or engagement features 255 that interact with the rotator elements 234 to provide such tactile feedback (see
The rotator elements 234 additionally or alternatively may abut and constrain distal translation of the inner limiter ring 210 and/or outer limiter ring 220 relative to the rotator 230, thereby limiting distal translation of the housing assembly 240 relative to the rotator. Translation of the housing assembly 240 relative to the rotator 230 additionally or alternatively may be constrained via engagement elements 235 that extend radially inward from rotator elements 234 and sit within reduced diameter cylindrical channel 259 of the housing assembly's cylindrical segment 254. The engagement elements 235 may comprise one-way valves that allow the rotator to be press fit over the housing assembly with the engagement elements 235 locking into position within the cylindrical channel 259. The engagement elements 235 facilitate rotation of the rotator relative to the housing assembly while constraining proximal (and optionally distal) translation of the housing assembly relative to the rotator.
As another technique for limiting proximal translation of the housing assembly relative to the rotator, a portion of the rotator shaft 232 optionally may flare slightly, while a distal portion of the housing shaft lumen 257 may be of reduced cross-section relative to a more proximal section of the lumen (not shown). The rotator shaft flaring may be of equal or just slightly greater cross-section than the reduced cross-section portion of the housing shaft lumen. During assembly of the handle 200, as the rotator 230 is coupled to the housing assembly 240 with the rotator shaft 232 positioned within the lumen 257 of the housing shaft 256, the rotator shaft flaring may engage and exert friction on the reduced cross-section portion of the housing shaft lumen 257. Continued distal advancement of the reduced cross-section portion of the housing shaft lumen 257 relative to the flaring of the rotator shaft 232 during assembly of the handle 200 may position the reduced cross-section portion of the housing shaft lumen distally of the rotator shaft flaring. In this configuration, the rotator shaft flaring may act as a press fit that constrains proximal translation of the housing assembly 240 relative to the rotator 230, while still allowing the rotator 230 to rotate relative housing assembly 240, i.e., via rotation of the rotator shaft 232 positioned within the lumen 257 of the housing shaft 256.
Distal translation of the housing assembly 240 relative to the rotator 230 may be constrained in a variety of ways, including those already mentioned. As another example, a distal end of the housing shaft 256 may abut a distal portion of the rotator 230. Alternatively or additionally, a proximal region of the rotator 230 may abut surface 241 of the housing assembly 240. As yet another example, an inner surface of the rotator may comprise one or more features or ridges 236 that extend radially inward from an inner surface of the rotator; the ridges may abut a distal surface of outer limiter ring 220 and/or inner limiter ring 210 to limit distal translation of the outer and/or inner limiter ring relative to the rotator 230, thereby limiting distal translation of the limiter rings and the housing assembly 240 relative to the rotator 230.
Rotation of the elongated shaft 16 relative to the handle assembly 200 may be limited in a variety of ways, e.g., may be limited to a predetermined or optimal number of rotations of the elongated shaft relative to the handle assembly in a variety of ways. In
As described in more detail below, caregiver rotation of the rotator 230 relative to the housing assembly 240 may cause the rotator tab 238 to abut outer tab 224, limiting further rotation of the rotator relative to the outer limiter ring 220; may cause the outer tab 224 to abut the inner arc tab 214, limiting further rotation of the outer limiter ring relative to the inner limiter ring 210; and may cause the inner arc tab 214 to abut the housing nub 258, limiting further rotation of the inner limiter ring relative to the housing assembly 240 and thereby limiting further rotation of the rotator relative to the housing assembly. As the elongated shaft 16 is coupled to the rotator 230, rotation of the elongated shaft relative to the handle assembly is thus also limited.
As best seen in
As also discussed previously, the inner diameter of the outer cylindrical segment 222 of the outer limiter ring 220 is just slightly greater than the outer diameter of the inner cylindrical segment 212 of the inner limiter ring 210 about which the outer cylindrical segment of the outer limiter ring is concentrically positioned, facilitating rotation of the outer limiter ring relative to the inner limiter ring. However, the outermost diameter of inner limiter ring 210 at inner arc tab 214 is greater than the outer diameter of the inner cylindrical segment 212 of the inner limiter ring (specifically, the outermost diameter of the inner limiter ring 210 at the inner arc tab 214 is roughly equal to the outer diameter of the outer cylindrical segment 222 of the outer limiter ring 220; thus, the inner arc tab does not interact with the rotator 230). Thus, when the outer limiter ring's outer tab 224, which extends longitudinally along and proximal of the outer limiter ring's outer cylindrical segment 222, is in rotational alignment with the inner arc tab 214 of the inner limiter ring 210, the inner limiter ring's inner arc tab 214 abuts the outer limiter ring's outer tab 224; this abutment constrains further rotation of the outer limiter ring relative to the inner limiter ring.
Again, as discussed previously, the inner diameter of a proximal region of rotator 230 is just slightly greater than the outermost diameter of the outer limiter ring 220 at outer tab 224, facilitating rotation of the rotator relative to the outer limiter ring. The outer diameter of the outer cylindrical segment 222 of the outer limiter ring 220 is less than the outermost diameter of the outer limiter ring 230 at outer tab 224. Rotator tab 238, which may extend longitudinally proximal from one of the ridges 236 on the inner surface of the rotator 230, extends radially inward from the inner surface of the rotator 230. The innermost diameter of the rotator 230 at the rotator tab 238 is smaller than the outermost diameter of the outer limiter ring 220 at the outer tab 224, but larger than the outer diameter of the outer cylindrical segment 222 of the outer limiter ring 220. Thus, when the rotator's rotator tab 238 is in rotational alignment with the outer limiter ring's outer tab 224, the rotator tab abuts the outer tab; this abutment constrains further rotation of the rotator 230 relative to the outer limiter ring 220.
Note that rotator tab 238 does not extend radially inward to the same extent as the ridges 236 of rotator 230. As such, whereas a distal surface of the cylindrical segment 222 of the outer limiter ring 220 may abut the ridges 236 in the assembled configuration of the handle 200, the outer cylindrical segment may be positioned within the rotator 230 concentric with the rotator tab 238. However, the outermost radius of the outer limiter ring 220 at outer tab 224 is such that rotation of the rotator 230 relative to the outer limiter ring until the rotator tab 238 is aligned with the outer tab 224 causes the rotator tab to abut the outer tab, thereby limiting further rotation of the rotator 230 relative to the outer limiter ring 220.
The abutments of rotator tab 238 of rotator 230 with outer tab 224 of outer limiter ring 220, of outer tab 224 with inner arc tab 214 of inner limiter ring 210, and of inner arc tab 214 with housing nub 258 of cylindrical segment 254 of housing assembly 240, limit rotation of the rotator 230 relative to the housing assembly 240. Continued caregiver rotation of the rotator 230 in a given direction relative to the housing assembly 240 causes the rotator tab 238 to abut outer tab 224, limiting further rotation of the rotator in the given direction relative to the outer limiter ring 220; causes the outer tab 224 to abut the inner arc tab 214, limiting further rotation of the outer limiter ring in the given direction relative to the inner limiter ring 210; and causes the inner arc tab 214 to abut the housing nub 258, limiting further rotation of the inner limiter ring in the given direction relative to the housing assembly 240 and thereby limiting further rotation of the rotator in the given direction relative to the housing assembly. Since the elongated shaft 16 is coupled to the rotator 230, rotation of the elongated shaft relative to the handle assembly is thus also limited.
The rotator 230 can rotate approximately one full revolution in a given direction before rotator tab 238 abuts the outer tab 224 of the outer limiter ring 220. Continued rotation of the rotator 230 in the given direction rotates the outer limiter ring 220 with the rotator until the outer limiter ring's outer tab 224 abuts the inner arc tab 214 of the inner limiter ring 210. Further continued rotation of the rotator 230 in the given direction rotates both the outer limiter ring and the inner limiter ring with the rotator until the inner arc tab 214 abuts the housing nub 258 of cylindrical surface 254 of the housing assembly 240, precluding any further rotation of the rotator in the given direction. Rotation of the rotator in the opposite direction can proceed for an equivalent number of revolutions before rotation is limited in that opposite direction.
The degree of rotation of the outer limiter ring 220 relative to the inner limiter ring 210, and of the inner limiter ring 210 relative to the housing assembly 240 is determined by the arc length of the inner arc tab 214 of the inner limiter ring 210. In the embodiment of
As will be apparent to those of skill in the art, by varying the arc length of the inner arc tab 214, the number of full revolutions of the rotator 230 relative to the housing assembly 240 may be varied to any desired degree between about 1 and 3 full revolutions (an arc length close to 360° would limit full rotations to about 1 rotation, while an arc length close to 0° would allow nearly 3 full rotations). As also will be apparent to those of skill in the art, the number of revolutions may be further expanded by utilizing additional limiter rings and tabs.
As best seen in
Referring now to
The housing assembly 240 also may comprise spring brake 310 having a spring 312 (e.g. a cantilevered compression spring) positioned on either side of channel 251 of the lower housing 244. As discussed previously, fin 281 of carrier 280 is positioned within the lower housing's channel 251. When utilizing spring brake 310, the springs 312 positioned on either side of the carrier's fin 281 press against the fin and increase friction during translation of the carrier 280. The magnitude of the friction force (static or sliding) applied to the carrier 280 may be specified as desired, e.g., through material selection of the carrier and the springs to obtain a desired coefficient of friction, through specification of the spring constant(s) of the springs 312 used in spring brake 310, and/or through the relative positioning of spring brake 310 and the carrier's fin 281 (i.e., through specification of the normal force applied to the fin 281). In another embodiment, spring brake 310 may comprise a single spring 312, which may be positioned on either side of lower housing channel 251 and carrier fin 281.
With reference to
As the actuator button 270 is rotated proximally within the actuator channel 250, thereby proximally translating the carrier 280 and deflecting the intermediate flexure zone 34 of the distal end region 20 via the control wire 40, the intermediate flexure zone 34 may convey a restoring moment to the actuator 260 through the control wire and the carrier. The restoring moment may seek to reverse deflection of the intermediate flexure zone and rotate the actuator button 270 back to a more distal position within the actuator channel 250. The increased friction provided by engagement of friction arm 268 against friction surface 253 may counteract the intermediate flexure zone's restoring moment to temporarily maintaining deflection of the intermediate flexure zone 34. Additional alternative friction and locking mechanisms known in the art may be provided.
As discussed previously, since there are cables and wires running from the handle assembly 200 through the elongated shaft 16 of the treatment device 12 (e.g., control wire 40, and supply wire(s) 29, such as electrical transmission wire(s), thermocouple wire(s), etc.), it is desirable to limit rotation of the shaft 16 relative to these wires in order to avoid unnecessary entanglement and twisting of these wires. The previously described rotational limiting element of handle assembly 200 addresses this need.
In the embodiment of
The rotator 230 and the housing assembly 240 can be configured to allow for the optimal number of revolutions for the shaft 16, given structural or dimensional constraints (e.g., wires). The components of the handle may be configured, for example, to allow for two revolutions of the shaft independent of the handle. Limiting rotation of the shaft to the optimal number of revolutions may be achieved, for example, by specifying the linear length of helical channel 120 of housing assembly 240 as a desired fraction or multiple of the inner circumference of rotator 230 in the vicinity of axial groove 116 (e.g., the linear length of helical channel 120 may be about twice the inner circumference of rotator 230 in the vicinity of axial groove 116). Additionally or alternatively, an additional ball 122 (not shown) may be positioned within the axial groove 116 spaced apart from the first ball 122, such that the additional ball travels within the helical channel 120 spaced apart from the first ball. In such an embodiment, the additional ball would limit rotation in one direction when that ball reaches one end of the channel, while the first ball would limit rotation in the other direction when that ball reaches the other end of the channel. In this manner, the two balls would limit rotation of the rotator to an arc length less than would otherwise be provided by the linear length of helical channel 120.
Referring now to
The rotation of the elongated shaft 16 when the intermediate flexure zone 34 is deflected within the respective renal artery rotates the thermal heating element 24 within the respective renal artery, making it easier to achieve contact with the vessel wall and determine whether there is wall contact, particularly in planes where there is poor angiographic visualization. Rotation may be combined with translation of the thermal heating element 24 for repositioning of the thermal heating element at a different radial and longitudinal position within the respective renal artery for delivery of energy at multiple locations within the renal artery.
As seen in
In an additional aspect of the disclosed technology, the handle 200 may be configured to minimize operator/caregiver handling of the device while it is within the patient. As shown in
Additional optional enhancements to the rotation mechanism disclosed herein include providing tactile and/or visual feedback on the rotator 230 so that the operator can exercise greater control and care in rotating the device. The rotator 230 also optionally may be selectively locked to the interface, thereby preventing further rotation, if the operator wishes to hold the treatment device in a particular angular position. Furthermore, the rotator 230 optionally may be coupled to the elongated shaft 16 via a rotation gearing mechanism, such that the degree of rotation of the rotator 230 is scaled to create more or less rotation of the elongated shaft 16.
Another optional enhancement includes providing distance markers along the shaft/handle to enable the operator to gage distance when retracting the treatment device. Yet another optional enhancement includes providing an alternative actuator that combines control of elongated shaft rotation relative to the housing assembly with control of elongated shaft distal region deflection. Still another optional enhancement includes providing an actuator on the handle assembly for controlling the delivery of energy, taking measurements, or activating a sensor. Another optional enhancement includes providing an audio or visual signal that indicates sensor feedback or amount of deflection or rotation.
Any one of the embodiments of the treatment devices 12 described herein can be delivered over a guide wire using conventional over-the-wire techniques. When delivered in this manner (not shown), the elongated shaft 16 includes a passage or lumen accommodating passage of a guide wire.
Alternatively, any one of the treatment devices 12 described herein can be deployed using a conventional guide catheter or pre-curved renal guide catheter (not shown).
When using a guide catheter, the femoral artery is exposed and cannulated at the base of the femoral triangle, using conventional techniques. In one exemplary approach, a guide wire (not shown) is inserted through the access site and passed using image guidance through the femoral artery, into the iliac artery and aorta, and into either the left or right renal artery. A guide catheter can be passed over the guide wire into the accessed renal artery. The guide wire is then removed. Alternatively, a renal guide catheter, which is specifically shaped and configured to access a renal artery, can be used to avoid using a guide wire. Still alternatively, the treatment device can be routed from the femoral artery to the renal artery using angiographic guidance and without the need of a guide catheter.
When a guide catheter is used, at least three delivery approaches can be implemented. In one exemplary approach, one or more of the aforementioned delivery techniques can be used to position a guide catheter within the renal artery just distal to the entrance of the renal artery. The treatment device is then routed via the guide catheter into the renal artery. Once the treatment device is properly positioned within the renal artery, the guide catheter is retracted from the renal artery into the abdominal aorta. In this approach, the guide catheter should be sized and configured to accommodate passage of the treatment device. For example, a 6 French guide catheter can be used.
In a second exemplary approach, a first guide catheter is placed at the entrance of the renal artery (with or without a guide wire). A second guide catheter is passed via the first guide catheter (with or without the assistance of a guide wire) into the renal artery. The treatment device is then routed via the second guide catheter into the renal artery. Once the treatment device is properly positioned within the renal artery the second guide catheter is retracted, leaving the first guide catheter at the entrance to the renal artery. In this approach the first and second guide catheters should be sized and configured to accommodate passage of the second guide catheter within the first guide catheter (i.e., the inner diameter of the first guide catheter should be greater than the outer diameter of the second guide catheter). For example, the first guide catheter could be 8 French in size and the second guide catheter could be 5 French in size.
In a third exemplary approach, a renal guide catheter is positioned within the abdominal aorta, just proximal to the entrance of the renal artery. The treatment device 12 as described herein is passed through the guide catheter and into the accessed renal artery. The elongated shaft 16 makes atraumatic passage through the guide catheter, in response to forces applied to force transmitting section 30 of the shaft through handle assembly 200. The proximal flexure zone 32 accommodates significant flexure at the junction of the left/right renal arteries and aorta to gain entry into the respective left or right renal artery through the guide catheter.
As seen in
As seen in
As previously described, the actuation of the control wire 40 to deflect the intermediate flexure zone 34 helps position the thermal heating element 24 in contact with the vessel wall. This is particularly useful when the distal end region 20 of the treatment device 12 is delivered into the renal artery. Due to the curve and placement of the (optional) renal guide catheter and orientation of the treatment device 12, the distal end region 20 of the treatment device may be oriented up against the superior region of the vessel wall when first delivered into the renal artery. Once the distal end region is positioned at the most distal portion of the main renal artery, the operator may deflect the intermediate flexure zone 34 via the actuator 260, which is coupled to carrier 280 and control wire 40, to position the thermal heating element 24 into contact with the vessel wall at a more inferior location, as shown in
The active deflection of intermediate flexure zone 34 is facilitated not only by operation of actuator 260, but also by contact between a proximal region of the intermediate flexure zone 34 and a superior region of the renal artery. As shown in
In certain embodiments, it may also be beneficial to equip the catheter apparatus with a second thermal heating element (not shown) at or in the vicinity of the intermediate flexure zone. Placement of the second thermal heating element on or proximate to the intermediate flexure zone may enable the creation of a thermally affected tissue region at or around contact region 124 (i.e., the portion of the vessel wall that is in contact with the intermediate flexure zone). Activation of the first thermal element and the second thermal element would allow the operator to create two treatment zones that are circumferentially and longitudinally offset during a single placement of the catheter apparatus.
As previously described, the thermal heating element 24 can be positioned by bending along the proximal flexure zone 32 at a first desired axial location within the respective renal artery. As
Once the thermal heating element 24 is positioned in the desired location by a combination of deflection of the intermediate flexure zone 34, deflection of the distal flexure zone 44 and rotation of the catheter, the first focal treatment can be administered. By applying energy through the thermal heating element 24, a first thermally affected tissue region 98(a) can be formed, as
After forming the first thermally affected tissue region 98(a), the catheter needs to be repositioned for another thermal treatment. It is desirable to create multiple focal lesions that are circumferentially spaced along the longitudinal axis of the renal artery. To achieve this result, the catheter is retracted and, optionally, rotated to position the thermal heating element proximally along the longitudinal axis of the blood vessel. Rotation of the elongated shaft 16 from outside the access site (see
Once the thermal heating element 24 is positioned at a second axial and circumferential location within the renal artery (e.g., 98(b)) spaced from the first-described axial position, as shown in
As described above, it may be desirable for the clinical treatment provider to use the treatment device to create multiple thermally affected treatment regions along the longitudinal axis of the blood vessel. Typically, the most distal treatment region would be created first and the treatment device would be retracted longitudinally to position the thermal element of the treatment device in subsequent proximal locations along the longitudinal axis of the blood vessel. In certain configurations it may be advantageous to separated sequential treatment regions by a specified distance (e.g., 5 mm). To achieve accurate and consistent separation between consecutive treatment regions, the treatment provider may decide to rely on the positioning of the thermal element from the previous treatment region as a reference point.
As shown in
This potential positioning concern described above can be addressed by reconfiguring the design of the handle and, particularly, the housing assembly 240, elongate shaft 16, control wire 40 and carrier 280. In the previously described embodiments, carrier 280 is proximally retracted upon operation of actuator 260 to apply tension to and axially retract control wire 40 relative to the elongated shaft 16. This tension will cause intermediate flexure zone 34 to deflect and/or buckle, thereby facilitating translation of thermal element 24. In the alternative embodiment illustrated in
Although the above described embodiment might facilitate accurate positioning and separation of the thermal element for consecutive treatment regions, coupling the elongated shaft to the carrier of the actuator assembly may compromise independent rotation of the shaft relative to the handle. One potential enhancement to address this concern would be to incorporate a rotational coupling (e.g., slip ring connector) into the handle assembly to allow for rotation of the elongated shaft independent of the housing assembly.
In an alternate embodiment, the housing assembly may be configured with a distal region and a proximal region wherein the distal region comprises a rotator to facilitate rotation of the distal region independent of the proximal region. In this embodiment, the distal region also includes the actuator assembly, which comprises the actuator and carrier, wherein the carrier is fixedly coupled to the carrier. In this configuration, the distal region of the housing assembly may rotate the elongated shaft independent of the proximal region of the housing assembly.
The above detailed descriptions of embodiments of the invention are not intended to be exhaustive or to limit the invention to the precise form disclosed above. Although specific embodiments of, and examples for, the invention are described above for illustrative purposes, various equivalent modifications are possible within the scope of the invention, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. As another example, the system 10 may have a different configuration and/or include different features, such as multi-thermal heating element devices, e.g., multi-electrode baskets or other balloon expandable devices that may be implemented to intravascularly deliver neuromodulatory treatment with or without contacting the vessel wall. The various embodiments described herein can also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the invention. Where the context permits, singular or plural terms may also include the plural or singular term, respectively. Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the invention. Accordingly, the invention is not limited except as by the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
09167937 | Aug 2009 | EP | regional |
09168202 | Aug 2009 | EP | regional |
09168204 | Aug 2009 | EP | regional |
The present application is a continuation-in-part of Patent Cooperation Treaty (PCT) Application No. PCT/US09/69334, filed Dec. 22, 2009, which claims the benefit of the following applications: (a) European Patent Application No. 09168202.1 filed Aug. 14, 2009; (b) European Patent Application No. 09168204.7, filed Aug. 14, 2009; (c) European Patent Application No. 09167937.3, filed Aug. 14, 2009; and (d) U.S. Provisional Patent Application No. 61/142,128, filed Dec. 31, 2008. Patent Cooperation Treaty (PCT) Application No. PCT/US09/69334, filed Dec. 22, 2009, is also a continuation-in-part of the following applications: (e) U.S. patent application Ser. No. 12/545,648, filed on Aug. 21, 2009, now U.S. Pat. No. 8,652,129; and (f) U.S. patent application Ser. No. 12/495,691, filed on Jun. 30, 2009. All of these applications are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
4602624 | Naples et al. | Jul 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4664113 | Frisbie et al. | May 1987 | A |
4764504 | Johnson et al. | Aug 1988 | A |
4976711 | Parins et al. | Dec 1990 | A |
5055109 | Gould et al. | Oct 1991 | A |
5114403 | Clarke et al. | May 1992 | A |
5185004 | Lashinski | Feb 1993 | A |
5195968 | Lundquist et al. | Mar 1993 | A |
5199950 | Schmitt et al. | Apr 1993 | A |
5217440 | Frassica | Jun 1993 | A |
5242430 | Arenas et al. | Sep 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5275151 | Shockey et al. | Jan 1994 | A |
5292315 | Euteneuer | Mar 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5308324 | Hammerslag et al. | May 1994 | A |
5318525 | West et al. | Jun 1994 | A |
5318526 | Cohen | Jun 1994 | A |
5327905 | Avitall | Jul 1994 | A |
5334145 | Lundquist et al. | Aug 1994 | A |
5352197 | Hammersmark et al. | Oct 1994 | A |
5354297 | Avitall | Oct 1994 | A |
5358478 | Thompson et al. | Oct 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5360406 | Boykin et al. | Nov 1994 | A |
5364351 | Heinzelman et al. | Nov 1994 | A |
5364352 | Cimino et al. | Nov 1994 | A |
5365928 | Rhinehart et al. | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5368592 | Stern et al. | Nov 1994 | A |
5391147 | Imran et al. | Feb 1995 | A |
5395327 | Lundquist et al. | Mar 1995 | A |
5395329 | Fleischhacker et al. | Mar 1995 | A |
5397304 | Truckai | Mar 1995 | A |
5399164 | Snoke et al. | Mar 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5431168 | Webster, Jr. | Jul 1995 | A |
5439006 | Brennen et al. | Aug 1995 | A |
5441483 | Avitall | Aug 1995 | A |
5445148 | Jaraczewski et al. | Aug 1995 | A |
5448989 | Heckele | Sep 1995 | A |
5456664 | Heinzelman et al. | Oct 1995 | A |
5465716 | Avitall | Nov 1995 | A |
5482037 | Borghi | Jan 1996 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5487757 | Truckai et al. | Jan 1996 | A |
5489270 | van Erp | Feb 1996 | A |
5545200 | West et al. | Aug 1996 | A |
5562619 | Mirarchi et al. | Oct 1996 | A |
5571147 | Sluijter et al. | Nov 1996 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5603697 | Grundy et al. | Feb 1997 | A |
5611777 | Bowden et al. | Mar 1997 | A |
5626576 | Janssen | May 1997 | A |
5643255 | Organ | Jul 1997 | A |
5656029 | Imran et al. | Aug 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5685878 | Falwell et al. | Nov 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5797842 | Pumares et al. | Aug 1998 | A |
5807249 | Qin et al. | Sep 1998 | A |
5823955 | Kuck et al. | Oct 1998 | A |
5827272 | Breining et al. | Oct 1998 | A |
5843076 | Webster, Jr. et al. | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5855560 | Idaomi et al. | Jan 1999 | A |
5860953 | Snoke et al. | Jan 1999 | A |
5865787 | Shapland | Feb 1999 | A |
5865800 | Mirarchi et al. | Feb 1999 | A |
5873842 | Brennen et al. | Feb 1999 | A |
5891088 | Thompson et al. | Apr 1999 | A |
5893885 | Webster et al. | Apr 1999 | A |
5897529 | Ponzi | Apr 1999 | A |
5935102 | Bowden et al. | Aug 1999 | A |
5935124 | Klumb et al. | Aug 1999 | A |
5938603 | Ponzi | Aug 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5951471 | de la Rama et al. | Sep 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
5987344 | West | Nov 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6027460 | Shturman | Feb 2000 | A |
6027473 | Ponzi | Feb 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6096036 | Bowe et al. | Aug 2000 | A |
6099524 | Lipson et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120476 | Fung et al. | Sep 2000 | A |
6135999 | Fanton et al. | Oct 2000 | A |
6146355 | Biggs | Nov 2000 | A |
6149620 | Baker et al. | Nov 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6171277 | Ponzi | Jan 2001 | B1 |
6179809 | Khairkhahan et al. | Jan 2001 | B1 |
6183463 | Webster, Jr. | Feb 2001 | B1 |
6198974 | Webster, Jr. | Mar 2001 | B1 |
6203525 | Whayne et al. | Mar 2001 | B1 |
6210362 | Ponzi | Apr 2001 | B1 |
6210407 | Webster | Apr 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6224587 | Gibson | May 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6246914 | de la Rama et al. | Jun 2001 | B1 |
6254568 | Ponzi | Jul 2001 | B1 |
6263224 | West | Jul 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6280423 | Davey et al. | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6314325 | Fitz | Nov 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6356790 | Maguire et al. | Mar 2002 | B1 |
6394976 | Winston et al. | May 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6468260 | Bumbalough et al. | Oct 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6500167 | Webster, Jr. | Dec 2002 | B1 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6511471 | Rosenman et al. | Jan 2003 | B2 |
6514226 | Levin et al. | Feb 2003 | B1 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6530897 | Nardeo | Mar 2003 | B2 |
6544215 | Bencini et al. | Apr 2003 | B1 |
6551271 | Nguyen | Apr 2003 | B2 |
6551302 | Rosinko et al. | Apr 2003 | B1 |
6562034 | Edwards et al. | May 2003 | B2 |
6569114 | Ponzi et al. | May 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6602278 | Thompson et al. | Aug 2003 | B1 |
6616624 | Kieval | Sep 2003 | B1 |
6616628 | Hayzelden | Sep 2003 | B2 |
6622731 | Daniel et al. | Sep 2003 | B2 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6736835 | Pellegrino et al. | May 2004 | B2 |
6776765 | Soukup et al. | Aug 2004 | B2 |
6783510 | Gibson et al. | Aug 2004 | B1 |
6783521 | Ponzi et al. | Aug 2004 | B2 |
6837867 | Kortelling | Jan 2005 | B2 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6850801 | Kieval et al. | Feb 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6926711 | Lentz et al. | Aug 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
6979319 | Manning et al. | Dec 2005 | B2 |
6987995 | Drysen | Jan 2006 | B2 |
7008401 | Thompson et al. | Mar 2006 | B2 |
7056314 | Florio et al. | Jun 2006 | B1 |
7063682 | Whayne et al. | Jun 2006 | B1 |
7077823 | McDaniel | Jul 2006 | B2 |
7101361 | Gardeski | Sep 2006 | B2 |
7122020 | Mogul | Oct 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7221979 | Zhou et al. | May 2007 | B2 |
7232422 | Gibson et al. | Jun 2007 | B2 |
7274957 | Drysen | Sep 2007 | B2 |
7285108 | Koerner et al. | Oct 2007 | B2 |
7300438 | Falwell et al. | Nov 2007 | B2 |
7374553 | Koerner et al. | May 2008 | B2 |
7377906 | Selkee | May 2008 | B2 |
7381200 | Katoh et al. | Jun 2008 | B2 |
7390894 | Weinshilboum et al. | Jun 2008 | B2 |
7402151 | Rosenman et al. | Jul 2008 | B2 |
7465288 | Dudney et al. | Dec 2008 | B2 |
7503914 | Coleman et al. | Mar 2009 | B2 |
7588555 | Pudelko et al. | Sep 2009 | B2 |
7591784 | Butler | Sep 2009 | B2 |
7591799 | Selkee | Sep 2009 | B2 |
7615044 | Scheibe et al. | Nov 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7618413 | Weitzner et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7632265 | Hauck et al. | Dec 2009 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7678074 | Fischer | Mar 2010 | B2 |
7678104 | Keidar | Mar 2010 | B2 |
7682358 | Gullickson et al. | Mar 2010 | B2 |
7691095 | Bednarek et al. | Apr 2010 | B2 |
7706894 | Stewart et al. | Apr 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7720517 | Drysen | May 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7771388 | Olsen et al. | Aug 2010 | B2 |
7778703 | Gross et al. | Aug 2010 | B2 |
7780648 | McIntyre et al. | Aug 2010 | B2 |
7803130 | Ryan et al. | Sep 2010 | B2 |
7811277 | Boulais | Oct 2010 | B2 |
7819857 | Ponzi et al. | Oct 2010 | B2 |
7828791 | Long et al. | Nov 2010 | B2 |
7842025 | Coleman et al. | Nov 2010 | B2 |
7853302 | Rodriguez et al. | Dec 2010 | B2 |
7879004 | Seibel et al. | Feb 2011 | B2 |
7881809 | Rashidi | Feb 2011 | B2 |
7892186 | Soukup et al. | Feb 2011 | B2 |
7909821 | Paddock et al. | Mar 2011 | B2 |
7917187 | Fuimaono et al. | Mar 2011 | B2 |
7931616 | Selkee | Apr 2011 | B2 |
7955314 | Fischer et al. | Jun 2011 | B2 |
7959601 | McDaniel et al. | Jun 2011 | B2 |
8002739 | Lee et al. | Aug 2011 | B2 |
8007462 | Gibson et al. | Aug 2011 | B2 |
8007463 | Pudelko et al. | Aug 2011 | B2 |
8021327 | Selkee | Sep 2011 | B2 |
8043288 | Dando et al. | Oct 2011 | B2 |
8048024 | Tah et al. | Nov 2011 | B2 |
8048025 | Barenboym et al. | Nov 2011 | B2 |
8048026 | Fischer et al. | Nov 2011 | B2 |
8131371 | Demarais et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8146603 | Thapliyal et al. | Apr 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
20020058910 | Hermann et al. | May 2002 | A1 |
20020165532 | Hill et al. | Nov 2002 | A1 |
20020183682 | Darvish | Dec 2002 | A1 |
20030040735 | Kunis et al. | Feb 2003 | A1 |
20030050681 | Pianca et al. | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030114832 | Kohler et al. | Jun 2003 | A1 |
20030125790 | Fastovsky et al. | Jul 2003 | A1 |
20030181897 | Thomas et al. | Sep 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20030208219 | Aznoian et al. | Nov 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20040010289 | Biggs et al. | Jan 2004 | A1 |
20040106897 | Thompson et al. | Jun 2004 | A1 |
20040116897 | Aboul- Hosn | Jun 2004 | A1 |
20040143197 | Soukup et al. | Jul 2004 | A1 |
20040215139 | Cohen | Oct 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20050004515 | Hart et al. | Jan 2005 | A1 |
20050004644 | Kelsch et al. | Jan 2005 | A1 |
20050080409 | Young et al. | Apr 2005 | A1 |
20050187579 | Danek et al. | Aug 2005 | A1 |
20050228460 | Levin et al. | Oct 2005 | A1 |
20050234523 | Levin et al. | Oct 2005 | A1 |
20050245862 | Seward et al. | Nov 2005 | A1 |
20050256452 | DeMarchi et al. | Nov 2005 | A1 |
20060025821 | Gelfand et al. | Feb 2006 | A1 |
20060041277 | Deem et al. | Feb 2006 | A1 |
20060047245 | Sehra | Mar 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060142695 | Knudson | Jun 2006 | A1 |
20060200047 | Galdonik et al. | Sep 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060212078 | Demarais et al. | Sep 2006 | A1 |
20060224111 | Rosenman et al. | Oct 2006 | A1 |
20060235474 | Demarais | Oct 2006 | A1 |
20060264820 | Ponzi et al. | Nov 2006 | A1 |
20060265014 | Demarais et al. | Nov 2006 | A1 |
20060265015 | Demarais et al. | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20060276852 | Demarais et al. | Dec 2006 | A1 |
20070066957 | Demarais et al. | Mar 2007 | A1 |
20070083239 | Demarais et al. | Apr 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070129761 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070156114 | Worley et al. | Jul 2007 | A1 |
20070156133 | McDaniel et al. | Jul 2007 | A1 |
20070173757 | Levine et al. | Jul 2007 | A1 |
20070173899 | Levin et al. | Jul 2007 | A1 |
20070213687 | Barlow | Sep 2007 | A1 |
20070225701 | O'Sullivan | Sep 2007 | A1 |
20070260225 | Sakakine et al. | Nov 2007 | A1 |
20070265609 | Thapliyal et al. | Nov 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20080051703 | Thornton et al. | Feb 2008 | A1 |
20080154190 | St. Germain et al. | Jun 2008 | A1 |
20080188800 | Bencini et al. | Aug 2008 | A1 |
20080188869 | Weitzner et al. | Aug 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20080255540 | Selkee | Oct 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20080287862 | Weitzner et al. | Nov 2008 | A1 |
20080319314 | Hill et al. | Dec 2008 | A1 |
20080319513 | Pu et al. | Dec 2008 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090062873 | Wu et al. | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090125001 | Anderson et al. | May 2009 | A1 |
20090171274 | Harlev et al. | Jul 2009 | A1 |
20090281524 | Scheibe et al. | Nov 2009 | A1 |
20090287188 | Golden et al. | Nov 2009 | A1 |
20090312698 | Farrell et al. | Dec 2009 | A1 |
20090326450 | Ostrovsky et al. | Dec 2009 | A1 |
20100004592 | Butler | Jan 2010 | A1 |
20100004633 | Rothe et al. | Jan 2010 | A1 |
20100010567 | Deem et al. | Jan 2010 | A1 |
20100022948 | Wilson et al. | Jan 2010 | A1 |
20100057150 | Demarais et al. | Mar 2010 | A1 |
20100063441 | Grunewald et al. | Mar 2010 | A1 |
20100069834 | Schultz | Mar 2010 | A1 |
20100087780 | Tekulve et al. | Apr 2010 | A1 |
20100106141 | Osypka et al. | Apr 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100137955 | Milijasevic et al. | Jun 2010 | A1 |
20100152582 | Thapliyal et al. | Jun 2010 | A1 |
20100168731 | Wu et al. | Jul 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100168740 | Stewart et al. | Jul 2010 | A1 |
20100174282 | Demarais et al. | Jul 2010 | A1 |
20100179512 | Chong et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100198040 | Friedman et al. | Aug 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100249773 | Clark et al. | Sep 2010 | A1 |
20100268307 | Demarais et al. | Oct 2010 | A1 |
20100312178 | Olsen et al. | Dec 2010 | A1 |
20100324538 | Van Orden | Dec 2010 | A1 |
20110021900 | Ponzi et al. | Jan 2011 | A1 |
20110054287 | Schultz | Mar 2011 | A1 |
20110054446 | Schultz | Mar 2011 | A1 |
20110054465 | Werneth et al. | Mar 2011 | A1 |
20110077498 | McDaniel | Mar 2011 | A1 |
20110077621 | Graham et al. | Mar 2011 | A1 |
20110184385 | Datta et al. | Jul 2011 | A1 |
20110196346 | Fischer et al. | Aug 2011 | A1 |
20120043088 | McAllister et al. | Feb 2012 | A1 |
20120059286 | Hastings et al. | Mar 2012 | A1 |
20120130289 | Demarais et al. | May 2012 | A1 |
20120130345 | Levin et al. | May 2012 | A1 |
20120172837 | Demarais et al. | Jul 2012 | A1 |
Number | Date | Country |
---|---|---|
102525646 | Jul 2012 | CN |
0521595 | Jan 1993 | EP |
1326550 | Jul 2003 | EP |
1968679 | Sep 2008 | EP |
2204134 | Jul 2010 | EP |
WO-9101772 | Feb 1991 | WO |
WO-9525472 | Sep 1995 | WO |
WO-9736548 | Oct 1997 | WO |
WO-0122897 | Apr 2001 | WO |
WO-0170114 | Sep 2001 | WO |
WO-0230310 | Apr 2002 | WO |
WO-2004098701 | Nov 2004 | WO |
WO 2004098701 | Nov 2004 | WO |
WO-2005041748 | May 2005 | WO |
WO-2005110528 | Nov 2005 | WO |
WO-2006022790 | Mar 2006 | WO |
WO-2006041847 | Apr 2006 | WO |
WO-2006041881 | Apr 2006 | WO |
WO-2006041881 | Apr 2006 | WO |
WO-2007008954 | Jan 2007 | WO |
WO-2007035537 | Mar 2007 | WO |
WO-2007078997 | Jul 2007 | WO |
WO-2007086965 | Aug 2007 | WO |
WO-2007103879 | Sep 2007 | WO |
WO-2007103881 | Sep 2007 | WO |
WO-2007121309 | Oct 2007 | WO |
WO-2007146834 | Dec 2007 | WO |
WO-2008003058 | Jan 2008 | WO |
WO-2008014557 | Feb 2008 | WO |
WO-2008061150 | May 2008 | WO |
WO-2008061152 | May 2008 | WO |
WO-2008070413 | Jun 2008 | WO |
WO-2010078175 | Jul 2010 | WO |
WO-2012033860 | Mar 2012 | WO |
Entry |
---|
U.S. Appl. No. 12/790,639, Wu et al. |
U.S. Appl. No. 12/871,457, Wu et al. |
U.S. Appl. No. 12/940,922, Gelfand et al. |
U.S. Appl. No. 12/996,897, Demarais. |
U.S. Appl. No. 13/007,370, Gelfand et al. |
U.S. Appl. No. 13/009,748, Beetel et al. |
U.S. Appl. No. 12/910,631, Wu et al. |
International Search Report and Written Opinion for PCT/US2009/069334; Applicant: Ardian, Inc.; Mailing Date: Mar. 1, 2010, 10 pages. |
International Search Report and Written Opinion, PCT/US05/35693, Mailed on Mar. 8, 2006, Applicant: Ardian, Inc., 29 pages. |
International Search Report and Written Opinion, PCT/US05/35757, Mailed on Dec. 27, 2006, Applicant: Ardian, Inc., 8 pages. |
International Search Report and Written Opinion, PCT/US06/36120, Mailed on Jun. 25, 2008, Applicant: Ardian, Inc., 10 pages. |
International Search Report and Written Opinion, PCT/US06/41889, Mailed on Oct. 20, 2008, Applicant: Ardian, Inc., 7 pages. |
International Search Report and Written Opinion, PCT/US06/48822, Mailed on Aug. 15, 2008, Applicant: Ardian, Inc., 12 pages. |
International Search Report and Written Opinion, PCT/US07/63322, Mailed on Mar. 3, 2008, Applicant: Ardian, Inc., 13 pages. |
International Search Report and Written Opinion, PCT/US07/63324, Mailed on Oct. 10, 2008, Applicant: Ardian, Inc., 13 pages. |
International Search Report and Written Opinion, PCT/US07/66539, Mailed on Jan. 28, 2008, Applicant: Ardian, Inc., 8 pages. |
International Search Report and Written Opinion, PCT/US07/70799, Mailed on Jul. 2, 2008, Applicant: Ardian, Inc., 7 pages. |
International Search Report and Written Opinion, PCT/US07/72396, Mailed on Aug. 27, 2008, Applicant: Ardian, Inc., 9 pages. |
International Search Report and Written Opinion, PCT/US07/84701, Mailed on Aug. 21, 2008, Applicant: Ardian, Inc., 11 pages. |
International Search Report and Written Opinion, PCT/US07/84705, Mailed on Jul. 28, 2008, Applicant: Ardian, Inc., 12 pages. |
International Search Report and Written Opinion, PCT/US07/84708, Mailed on Aug. 11, 2008, Applicant: Ardian, Inc., 9 pages. |
International Search Report, PCT/US04/38498, Mailed Feb. 18, 2005, Applicant: G & L Consulting, LLC, 4 pages. |
European Search Report; European Patent Application No. 09156661.2; Applicant: Ardian, Inc.; Date of Mailing: Jul. 23, 2009, 6 pages. |
European Search Report; European Patent Application No. 09167937.3; Applicant: Ardian, Inc.; Date of Mailing: Nov. 11, 2009, 6 pages. |
European Search Report; European Patent Application No. 09168202.1; Applicant: Ardian, Inc.; Date of Mailing: Nov. 11, 2009, 5 pages. |
European Search Report; European Patent Application No. 09168204.7; Applicant: Ardian, Inc.; Date of Mailing: Nov. 19, 2009, 6 pages. |
Ardian Medtronic LLC, International Search Report and Written Opinion dated Nov. 22, 2011, International Application No. PCT/US2011/030496, 15 pages. |
Avitall et al., “The Creation of Linear Contiguous Lesions in the Atria with an Expandable Loop Catheter”; Journal of the American College of Cardiology, 1999; vol. 33, No. 4; pp. 972-984, located online at: http://content/onlinejacc.org/cgi/content/full/33/4/972. |
Excerpt of Operator's Manual, 110V; Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
Excerpt of Operator's Manual, 150; Boston Scientific, “Maestro 3000 Cardiac Ablation System”, Version of Oct. 17, 2005, Ref. Catalog No. 21020, (4 pages). |
Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011 (26 pages). |
Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012 (25 pages). |
Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011 (20 pages). |
Wittkampf et al., “Control of Radiofrequency Lesion Size by Power Regulation”; Circulation: Journal of the American Heart Association; 1989, vol. 80: pp. 962-968, located online at: http://circ.ahajournals.org/content/80/4/962. |
Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” J Clin Invest, 1975;56:208-217. |
Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” J Clin Invest, 1976:57:1104-1107. |
Bhandari, A. and Ellias, M., “Loin Pain Hemaluria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327. |
Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
Dibona, Gerald F. and Ulla C. Kopp, “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, the American Physiological Society 1997, pp. 75-197. |
Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrenal Norepinephrine Infusion in Conscious Rats”. |
Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” in Proceedings of the Society for Experimentla Biology and Medicine, vol. 168, 77-81, 1981. (Abstract). |
Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009. |
Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implictions for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
USRDS United States Renal Data System 2003 Annual Data Report. |
U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
Benito, F., et al. “Radiofrequency cateheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
Dibona, G.F. “Sympathetic nervous system and kidney in hypertension.” Nephrol and Hypertension, 11:197-200 (2002). |
Dibona, G.F., et al. “Neural control of renal function.” Physiol Rev, 77:75-197 (1997). |
Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
Han, Y.-M, et al., “Renal artery ebolization with diluted hot contrast medium: An experimental study.” J Vasc Interv Radiol, 12: 862-868 (2001). |
Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats.” Hypertension 32 (1998) pp. 249-254. |
Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
Lee, S.J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
Lustrgarten, D.L.,et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
Oliverira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation.” Circulation, 102:2774-2780 (2000). |
Smithwick et al., “Splanchnicectomy for essential hypertension.” J. Am. Med. Assn. 152:16 (1953), pp. 1501-1504. |
Solis-Herruzo et al., “Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome,” J. Hepatol. 5 (1987), pp. 167-173. |
Stella, A., et al., “Effects of reversible renal deneravation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
Swartz, J.F., et al., “Radiofrequency endocardial cateheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
Valente, J.F. “Laparoscopic renal denervation for intractable ADPKD-related pain.” Nephrol Dial Transplant, 16: 160 (2001). |
Weinstock, M., et al., “Renal denervation prevents sodium rentention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
Curtis, J.J., et al., “Surgical therapy for presistent hypertension after renal transplantation.” Trasnplantation, Feb. 1981, vol. 31, pp. 125-128. |
Gelfand, M., et al., “Treatment of renal failure and hypertension” U.S. Appl. No. 60/442,970 dated Jan. 29, 2003. |
Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361;9. |
Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16:160. |
Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardian Electrophysiology, 2001, pp. 401-410. |
“2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct—2011.php>. |
“2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
“Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
“Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=622732&p=irol-newsArticle&id=1756108>. |
“Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media—relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
“Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news—latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
“Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
“Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
“Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
“Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
“The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
“The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
“Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
Asbell, Penny, “Conductive Keratoplasty for the Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global Symplicity registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines—article&forceid=83002>. |
Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
Final Office Action; U.S. Appl. No. 12/827,700; Mailed on Feb. 5, 2013, 61 pages. |
Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
Gertner, Jon, “Meet the Tech Duo That's Revitalizing the Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988), 39 pages. |
Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
Imimdtanz, “Medtronic awarded industry's highest honour for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011), 44 pages. |
Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines—article&forceid=80880>. |
Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
Sievert, Horst, “Novelty Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
Stouffer, G. A. et al., Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6 pages, www.clinicaltrials.gov/ct2/show/NCT01390831. |
Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages, http://clinicaltrials.gov/ct2/show/NCT01628198. |
Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.html>. |
Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003), p. 151-152, 198, 284-286. |
ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, 2003, 23 pages. |
Curtis, J. J., et al., “Surgical therapy for persistent hypertension after renal transplantation.” Transplantation, 1981, 31: 125-128. |
International Search Report and Written Opinion for International App. No. PCT/US11/30496, Date Mailed Nov. 22, 2011, 16 pages. |
Number | Date | Country | |
---|---|---|---|
20100249773 A1 | Sep 2010 | US |
Number | Date | Country | |
---|---|---|---|
61142128 | Dec 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2009/069334 | Dec 2009 | US |
Child | 12759641 | US | |
Parent | 12545648 | Aug 2009 | US |
Child | PCT/US2009/069334 | US | |
Parent | 12495691 | Jun 2009 | US |
Child | 12545648 | US |